Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

Nice to see some good news on a s**t day!

.

Objective Capital have issued a new report on CEN saying the failure to meet the primary endpoint for PIII M6G in the nausea indication, will necessitate a further Phase 3 trial (probably as part of a US Phase 3 trial) and delay launch until 2010.

Looks like 4.50/5.oo back on the cards then,and back to bottom draw.

Alan Goodman, Chairman of CeNeS, said:

"CeNeS has taken a major step forward in the development of M6G and is now well
placed to successfully commercialise its lead asset. The partnering process has
begun and the Company is well positioned to deliver significant value to
shareholders in the near-term."

From the finals. We shall see. Only time will tell.

Agree long term bottom drawer!

Some news-

FDA approves IND on Lead Product M6G

Cambridge, UK, 26th April 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, today announces that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of morphine-6-glucuronide (M6G), its novel drug for the treatment of post-operative pain. Earlier this year, CeNeS announced results of a Phase III study of M6G in Europe in over 500 patients with post-operative pain. The study demonstrated that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV).
The opening trial under this IND will be a Phase I pharmacokinetic study in volunteers. This study is required by the FDA as is an additional pre-clinical toxicology analysis before progressing to Phase III trials. CeNeS is currently completing the protocol design of the first US Phase III trial. The filing of the IND enhances the package of data already available to potential US partners for review.
Neil Clark, Chief Executive of CeNeS, said:

"The FDAs approval of our IND application for M6G is a major landmark in CeNeS clinical development programme. North America is an attractive market for our drug candidate and M6G is clearly positioned to be a genuine alternative to standard morphine therapy."

More good news then - but if the SP history of CEN is any guide I suspect we'll head south from here!

Not a one-trick pony:

CeNeS Pharmaceuticals PLC said the data from an independent study published in the scientific journal Synapse supports and extends the company's original findings with its potential treatment for neuropathic pain, CNS 5161.

The biopharmaceutical company said it plans to test the drug in further phase II trials in cancer pain and neuropathic pain later in the year.

Some news.

UK, 4th May 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, notes the publication of an independent study in the respected scientific journal 'Synapse'* on its Phase II NMDA antagonist, CNS 5161. CeNeS is developing CNS 5161 as a potential treatment for neuropathic pain. The independent study builds on the work that CeNeS has already undertaken with CNS 5161.

In the study reported in 'Synapse', Dr Anat Biegon and her group at the Brookhaven National Laboratory, New York, USA, have studied a radioactively labelled version of CNS 5161. They have shown that CNS 5161 is a selective and high affinity NMDA receptor antagonist with preferential binding to the activated form of the receptor. The group also demonstrated that CNS 5161 penetrates the brain well and can be used to label selectively brain NMDA receptors in vivo. Dr Biegon proposes that a radioactive form of CNS 5161 may be used as an agent to monitor NMDA receptors in the human brain using Positron Emission Tomography ("PET") and notes that "the significance of a selective, validated radiopharmaceutical agent suitable for detecting widespread as well as highly localized changes in the NMDA receptor in the living brain cannot be exaggerated".

Data from Phase I and Phase IIa studies previously carried out by CeNeS have shown that CNS 5161 has analgesic properties in patients with neuropathic pain, but does not induce the severe psychotomimetic side-effects associated with other NMDA antagonists.

Neil Clark, Chief Executive of CeNeS, said:

"The data published in this paper supports and extends our original findings with CNS 5161. It has proved very difficult to develop a PET agent with the properties that make it possible to monitor NMDA receptor activation in the human brain. The profile of CNS 5161 as a selective, high affinity and brain-penetrating agent now make this a possibility. These properties of CNS 5161, together with its low liability to induce side-effects, are the scientific foundation for our clinical development programme of CNS 5161 as a novel treatment for the major neuropathic pain market. We plan to test CNS 5161 in further Phase II trials in cancer pain and neuropathic pain later this year."

*In vitro and in vivo characterization of [3H]CNS-5161. A use-dependent ligand for the N-methyl-d-aspartate receptor in rat brain. Biegon et al., Synapse, volume 61, pages 577-586, 2007.

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About CNS 5161 A range of primary diseases or conditions such as diabetes, cancer, HIV/Aids and shingles, or surgical procedures such as limb amputation can result in nerve damage which leads to a sustained chronic pain. This neuropathic pain is difficult to treat as traditional analgesics do not provide adequate relief for many patients. Drug treatments for neuropathic pain represent a significant area of unmet medical need and a growing market opportunity that is currently valued at over $2 billion globally. Glutamate (particularly NMDA) receptors have been implicated in the induction and maintenance of neuropathic pain and NMDA antagonists may represent a class of drugs for effective relief of neuropathic pain. CNS 5161 is a blocker of the NMDA ion channel and has completed Phase I and more recently Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain. Two Phase I studies using CNS 5161 administered intravenously have been completed in male volunteers. The first study demonstrated the safety and tolerability of selected doses of CNS 5161 and the second that at a dose of CNS 5161 that was well tolerated, analgesic effects were evident in an experimental model of pain. Two phase IIa studies have been completed giving single dose intravenous infusions of CNS 5161 to patients with long standing intractable neuropathic pain. A total of 48 patients have received CNS 5161; 10 patients in an initial study and 38 patients in a study completed in 2005. Both studies reported analgesic effects of CNS 5161 at doses that were well tolerated by the patients

Some more positive up to date news (Abridged for copyright reasons):-

CeNeS Pharmaceuticals plc

Statistical analysis of the recent Phase III trial on Lead Product M6G shows additional benefits



Statistically significant reduction in sedation during the early post-operative period compared to morphine



Statistically significant reduction in nausea in the female patient population compared to morphine



Cambridge, UK, 8th June 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company, announces additional data from post-hoc analysis of the recent Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. The Phase III data released on 20 February 2007 confirmed M6Gs planned product profile and showed that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV).



Sedation



Analysis of the sedation data from the M6G022 trial showed statistically significant reductions in sedation in the M6G group compared to morphine in the first four hours after surgery reaching a reduction of 15% at 4 hours (p=0.007). Discussions with clinicians support the view that this is a clinically important benefit. Opiates such as morphine are well known to induce sedation and respiratory depression. Excessive sedation in the early post-operative period is associated with depression of the respiratory system, which can, in some cases, be fatal.



Nausea in female patients



It is well established that female patients undergoing surgery have a higher risk of experiencing nausea and vomiting in the post-operative period. New data analysing the female patient group (approximately 70% of the patients in the M6G022 Phase III clinical trial) showed a statistically significant reduction in nausea in the period 624 hours after treatment (p=0.034). The overall incidence and severity of post-operative nausea in the M6G arm for both males and females was 27% less than that observed in the morphine arm but narrowly missed statistical significance, p=0.052 (versus target of p<0.05), as previously reported. This was the second primary endpoint.


Chief Executive of CeNeS, commented: This further analysis of the recent Phase III trial data supports our stated goal of delivering M6G to the market as a novel analgesic for post-operative pain that has clearly defined benefits compared to morphine and other opiates. The large body of statistically significant Phase III efficacy and side effect/safety data also suggest that M6G could be uniquely positioned as an opiate analgesic for day case surgery an additional growing market to the current focus on hospital based post-operative pain.



It is estimated that at least 277 million units of injectable analgesics were used to treat pain in the United States in 2006. The US post-operative pain market is estimated to be $1.7 billion. CeNeS is confident that M6G will establish a strong position in the large global pain market.

Good news indeed. Shame its come on such a bad day for the markets otherwise I suspect the SP would have reacted more positively.

Hi Queen, not just good news GREAT news. All of a sudden "females" are having the benefits we invested in. What about males? I am sure there must be more great news to come for "males". M6G has been hell of a ride for the last 5 years and I sure it will be for time to come. Mind, I wouldn't be against one of these hedge funds coming in at 60p a share!

Queenie ... its a crock of sh*te imo .

Regards

Dildo - just like your c*ck when the sheep are around, you just can't keep your evil, foul-smelling opinions to yourself can you. But thanks for such an informative post, it's added immeasurable substance and depth to the thread.

Regards

Hey, nice one Queenie!

Merci parthus

Just had another look Queenie and your p*ssing in the wind mate.

Go and buy something tidy for once in you life.

Regards

xxx

Dilbert it's taken you 2 whole days to come up with that response. Is that really the best you could do?! Perhaps the sheep on the top field weren't playing the game and kept running for cover. Either way, as ever your insightful commentary has kept myself and other posters glued to the edge of their keyboards and we thank you for your infinite wisdom.

No probs mate , just ask I'm always willing to help a dickhead .